Economics of Formulary Design and Mental Health Policy
处方设计和心理健康政策的经济学
基本信息
- 批准号:7070023
- 负责人:
- 金额:$ 14.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-07-15 至 2008-05-31
- 项目状态:已结题
- 来源:
- 关键词:Medicare /Medicaidantidepressantsbehavioral /social science research tagclinical researchdecision makingfluoxetinehealth care cost /financinghealth care policyhealth care qualityhealth care service availabilityhealth care service utilizationhealth economicshealth insurancehuman datapatient care managementpharmacy administrationpostdoctoral investigatorpsychopharmacologic agentpsychopharmacologypsychotropic drugsserotonin inhibitortherapy compliance
项目摘要
DESCRIPTION (provided by applicant): Prescription drugs have become an increasingly important component of mental health treatment and the costs of psychotropic drugs have increased rapidly in recent years. However, there are major gaps in our knowledge about the economics of psychotropic drug treatment. This Mentored Research Scientist Development Award would allow Dr. Haiden Huskamp, a health economist with expertise in mental health policy and economic institutions, to supplement her economic tools with the knowledge and skills needed to conduct clinically-relevant and policy-significant research on the economics of prescription drugs used in the treatment of mental illnesses. The specific aims of this career development proposal are to: 1) develop a greater understanding of clinical decision-making related to the use of psychotropic drugs; 2) acquire basic knowledge of psychopharmacology; and 3) expand knowledge of the important economic institutions influencing the prescription drug market. In this undertaking, Dr. Huskamp will be guided by her sponsor, Richard Frank, PhD, and co-sponsors, Andrew Nierenberg, MD, and Ernst Berndt, PhD. Her career development plan includes guided study with Dr. Nierenberg on clinical issues related to treatment decision-making and Drs. Berndt and Frank on economic institutions of the pharmaceutical market, as well as coursework and participation in psychopharmacological "Grand Rounds," relevant seminar series, and professional meetings. Dr. Huskamp will use the knowledge and skills developed through these career development activities to conduct three research projects. The first project examines the effect of generic entry in the class of selective serotonin reuptake inhibitors (SSRls) on utilization patterns, costs, and market share among antidepressants as well as the competitive response of brand antidepressant manufacturers with respect to drug prices and promotional spending. The second project assesses the economic incentives created by three-tier drug formularies and how these arrangements affect costs, utilization patterns, and adherence to treatment guidelines in a non-elderly population. This project includes an economic welfare analysis of the tradeoffs associated with restrictive formularies. The third project examines the effect of a three-tier formulary on psychotropic drug costs and utilization patterns in a retiree population and explores the impact of formularies on the mental health costs of adding a prescription drug benefit to Medicare and on access to appropriate psychotropic drug treatment under such a benefit. The proposed plan of career development will provide Dr. Huskamp the training, mentoring, time and resources to develop the skills that will put her in a position to lead independent research on the economics of pharmaceutical treatment for mental illnesses.
描述(申请人提供):处方药已成为精神卫生治疗的一个越来越重要的组成部分,近年来精神药物的成本迅速增加。然而,我们对精神药物治疗的经济学知识存在重大差距。海登·赫斯坎普博士是一位在精神卫生政策和经济机构方面具有专业知识的健康经济学家,通过这项有指导意义的研究科学家发展奖,她可以为自己的经济工具补充所需的知识和技能,以便对用于治疗精神疾病的处方药的经济学进行具有临床相关性和重大政策意义的研究。这项职业发展建议的具体目的是:1)更好地了解与使用精神药物有关的临床决策;2)获得精神药理学的基本知识;3)扩大对处方药市场有影响的重要经济机构的知识。在这项工作中,赫斯坎普博士将由她的赞助人理查德·弗兰克博士、共同赞助人安德鲁·尼伦伯格医学博士和恩斯特·伯恩特博士指导。她的职业发展计划包括与尼伦伯格博士就与治疗决策相关的临床问题进行指导研究,与Berndt博士和Frank博士就药品市场的经济机构进行指导研究,以及课程作业和参与精神药理学“大轮回”、相关研讨会系列和专业会议。赫斯坎普博士将利用通过这些职业发展活动获得的知识和技能进行三个研究项目。第一个项目考察了选择性5-羟色胺再摄取抑制剂(SSRL)的仿制药进入对抗抑郁药的使用模式、成本和市场份额的影响,以及品牌抗抑郁药制造商在药品价格和促销支出方面的竞争反应。第二个项目评估三级药物处方创造的经济激励,以及这些安排如何影响非老年人口的成本、使用模式和对治疗指南的遵守。这个项目包括对与限制性公式相关的权衡的经济福利分析。第三个项目审查了三级处方对退休人口中精神药物费用和使用模式的影响,并探讨了处方对将处方药福利添加到医疗保险中的精神健康成本以及在这种福利下获得适当精神药物治疗的影响。拟议的职业发展计划将为赫斯坎普博士提供培训、指导、时间和资源,以培养她的技能,使她能够领导精神疾病药物治疗经济学的独立研究。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.
价格、利润和创新:审视对新精神药物价值的批评。
- DOI:10.1377/hlthaff.25.3.635
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Huskamp,HaidenA
- 通讯作者:Huskamp,HaidenA
Part D and dually eligible patients with mental illness: medication access problems and use of intensive services.
D 部分和双重资格的精神疾病患者:药物获取问题和强化服务的使用。
- DOI:10.1176/ps.2009.60.9.1169
- 发表时间:2009-09
- 期刊:
- 影响因子:0
- 作者:Huskamp HA;West JC;Rae DS;Rubio-Stipec M;Regier DA;Frank RG
- 通讯作者:Frank RG
Economic grand rounds: potential effects of the new medicare drug benefit on pricing for psychotropic medications.
经济大轮:新医疗保险药物福利对精神药物定价的潜在影响。
- DOI:10.1176/appi.ps.56.9.1056
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Huskamp,HaidenA;Shinogle,JudithA
- 通讯作者:Shinogle,JudithA
The new medicare drug benefit: formularies and their potential effects on access to medications.
新的医疗保险药物福利:处方集及其对药物获取的潜在影响。
- DOI:10.1111/j.1525-1497.2005.0110.x
- 发表时间:2005
- 期刊:
- 影响因子:5.7
- 作者:Huskamp,HaidenA;Keating,NancyL
- 通讯作者:Keating,NancyL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HAIDEN A. HUSKAMP其他文献
HAIDEN A. HUSKAMP的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HAIDEN A. HUSKAMP', 18)}}的其他基金
Medications for Alcohol Use Disorder: Unfilled Prescriptions and Treatment Trajectories
治疗酒精使用障碍的药物:未配处方和治疗轨迹
- 批准号:
10436953 - 财政年份:2021
- 资助金额:
$ 14.05万 - 项目类别:
Medications for Alcohol Use Disorder: Unfilled Prescriptions and Treatment Trajectories
治疗酒精使用障碍的药物:未配处方和治疗轨迹
- 批准号:
10598575 - 财政年份:2021
- 资助金额:
$ 14.05万 - 项目类别:
Telemedicine for Treatment of Opioid Use Disorder
治疗阿片类药物使用障碍的远程医疗
- 批准号:
10169552 - 财政年份:2019
- 资助金额:
$ 14.05万 - 项目类别:
Telemedicine for Treatment of Opioid Use Disorder: NIDA Summer Research Internship Program
用于治疗阿片类药物使用障碍的远程医疗:NIDA 夏季研究实习计划
- 批准号:
10402983 - 财政年份:2019
- 资助金额:
$ 14.05万 - 项目类别:
Telemedicine for Treatment of Opioid Use Disorder
治疗阿片类药物使用障碍的远程医疗
- 批准号:
10382265 - 财政年份:2019
- 资助金额:
$ 14.05万 - 项目类别:
Telemedicine for Treatment of Opioid Use Disorder
治疗阿片类药物使用障碍的远程医疗
- 批准号:
10152467 - 财政年份:2019
- 资助金额:
$ 14.05万 - 项目类别:
Use of Telemedicine in the Treatment of Mental Illness
远程医疗在精神疾病治疗中的应用
- 批准号:
10442011 - 财政年份:2017
- 资助金额:
$ 14.05万 - 项目类别:
Use of Telemedicine in the Treatment of Mental Illness
远程医疗在精神疾病治疗中的应用
- 批准号:
10599349 - 财政年份:2017
- 资助金额:
$ 14.05万 - 项目类别:
Center to Improve System Performance of Substance Use Disorder Treatment
提高药物滥用治疗系统性能中心
- 批准号:
10494628 - 财政年份:2015
- 资助金额:
$ 14.05万 - 项目类别:
相似国自然基金
早年心理应激对大鼠抑郁样行为及突触可塑性的影响
- 批准号:81171284
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
相似海外基金
Stratification of depression based on lysophospholipid metabolic disorders and innovative development of novel antidepressants
基于溶血磷脂代谢紊乱的抑郁症分层及新型抗抑郁药的创新开发
- 批准号:
23H02839 - 财政年份:2023
- 资助金额:
$ 14.05万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The role of antidepressants in central and peripheral myeloid HIV persistence and inflammation
抗抑郁药在中枢和外周髓系 HIV 持续存在和炎症中的作用
- 批准号:
10762810 - 财政年份:2023
- 资助金额:
$ 14.05万 - 项目类别:
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
单相重度抑郁症药物的优化预测治疗 (OPTIMUM-D)
- 批准号:
469292 - 财政年份:2022
- 资助金额:
$ 14.05万 - 项目类别:
Operating Grants
Concomitant use of antidepressants and oral antidiabetic drugs and the risk of hypoglycemia
抗抑郁药和口服抗糖尿病药的同时使用和低血糖的风险
- 批准号:
10679095 - 财政年份:2022
- 资助金额:
$ 14.05万 - 项目类别:
Molecular and behavioural consequences of maternal depression and antidepressant use during pregnancy
孕期母亲抑郁症和抗抑郁药使用的分子和行为后果
- 批准号:
473680 - 财政年份:2022
- 资助金额:
$ 14.05万 - 项目类别:
Fellowship Programs
Concomitant use of antidepressants and oral antidiabetic drugs and the risk of hypoglycemia
抗抑郁药和口服抗糖尿病药的同时使用和低血糖的风险
- 批准号:
10526807 - 财政年份:2022
- 资助金额:
$ 14.05万 - 项目类别:
Reelin, sex, depression, and development of a novel pharmacotherapy and biomarkers
Reelin、性、抑郁症以及新型药物疗法和生物标志物的开发
- 批准号:
477287 - 财政年份:2022
- 资助金额:
$ 14.05万 - 项目类别:
Operating Grants
The Effect of Energy Spectrum on Light Therapy
能谱对光疗的影响
- 批准号:
466966 - 财政年份:2021
- 资助金额:
$ 14.05万 - 项目类别:
Studentship Programs
Leveraging Rapid-Acting Antidepressants for Personalized Response
利用速效抗抑郁药进行个性化治疗
- 批准号:
10387133 - 财政年份:2021
- 资助金额:
$ 14.05万 - 项目类别:
Utility of the Human Connectome for Predicting Antidepressant Treatment Response
人类连接组用于预测抗抑郁治疗反应的实用性
- 批准号:
454848 - 财政年份:2021
- 资助金额:
$ 14.05万 - 项目类别:
Fellowship Programs